GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Name | Title | Since | Age |
|---|---|---|---|
| Luis J. Malave | Independent Chairman | 2024 | 63 |
| Erik C. Emerson | CEO & Director | 2026 | 55 |
| Paul V. Goode | Chief Technical Officer, President & Director | 2026 | 58 |
| Avner Gal | Co-Founder, Chairman Emeritus & Consultant | 2017 | 72 |
| David C. Klonoff | Chair of Scientific Advisory Board | 2021 | - |
| Erin Carter | Independent Director | 2023 | 56 |
| Guillermo E. Umpierrez | Chair of Medical Advisory Board | 2025 | - |
| Victoria E. Carr-Brendel | Independent Director | 2025 | 62 |
| Andrew K. Balo | Independent Director | 2024 | 78 |
| Usman Latif | Member of Clinical Advisory Board | 2025 | - |
| David S. Hirsh | Clinical & Scientific Advisor | 2025 | - |